BCM
BEAM icon

Bayesian Capital Management’s Beam Therapeutics BEAM Stock Holding History

Bayesian Capital Management’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-8,803
Closed -$291K – 741
2024
Q1 		$291K Buy
+8,803
New +$274K 0.03% 558
2022
Q2 		– Sell
-8,100
Closed -$464K – 787
2022
Q1 		$464K Buy
+8,100
New +$531K 0.07% 394

Other funds holding BEAM

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Bayesian Capital Management's BEAM Position: Q2 2024 in Review

Bayesian Capital Management sold out of Beam Therapeutics (BEAM) in Q2 2024, closing a stake of 8,803 shares — an estimated $291K sold.

Bayesian Capital Management first reported a position in BEAM in Q1 2022 and held it in 2 quarters. The position peaked at $464K in Q1 2022. 214 funds tracked by Wall St. Rank hold BEAM as of Q2 2024.

  • Bayesian Capital Management reported no remaining Beam Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Bayesian Capital Management sold 8,803 Beam Therapeutics shares in Q2 2024, an estimated $291K.
  • Bayesian Capital Management first reported a position in Beam Therapeutics in Q1 2022 and held it in 2 quarters.
  • Bayesian Capital Management's Beam Therapeutics position peaked at $464K in Q1 2022.
  • 214 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2024.

Based on Bayesian Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.